Saturday, November 24, 2012

The 2012 fungal meningitis outbreak: Whose fault?


Continue reading here

Updated: 11/24/2012 9:55:47 AM EST Health Dept. Takes Action Against Pharmacy A compounding pharmacy in Tamarac has been suspended, following a less than glowing inspection.

by Alan McBride

Florida Department of Health issued an Emergency Suspension Order of People's Choice Pharmacy, a compounding pharmacy located in Tamarac.

The order immediately suspended People's from operating as a community, sterile products, and special compounding pharmacy in the state of Florida.

The order comes after the department had conducted a routine pharmacy inspection of People's Choice Pharmacy in mid-October.

The inspection revealed that the pharmacy lacked quality assurance in high-risk sterile compounding.

It was also found that the pharmacy's use of unlicensed personnel for high-risk sterile compounding endangered the public.

The Department found further that People's Choice Pharmacy's failure to maintain adequate sanitation increased the likelihood that the medications compounded at this facility may become contaminated.

The issues inspectors reported finding gain substantially more public attention in the wake of a scandal involving tainted steroidal compounds.

the company NECC has been all but shuttered after medicine it compounded was traced to cases of fungal meningitis.

There have been three deaths in Florida as a result of fungal meningitis.

Emergency suspension or restriction orders are not considered final agency action but are imposed when the subject's actions pose an immediate serious danger to public health, as specified by section 456.074, Florida Statutes.

The subject is entitled to a hearing before final action is taken by a regulatory board or by DOH.

The suspension, however, will remain in effect until final disciplinary action is taken, the suspension is lifted, or the case is successfully appealed.

15 meningitis lawsuits filed in N.J. over tainted steroids


FRIDAY NOVEMBER 23, 2012, 11:03 PM
THE RECORD

Fifteen lawsuits, including nine this week, have been filed in New Jersey by patients exposed to or sickened by fungal meningitis in the fatal nationwide outbreak caused by tainted steroid medication.
The lawsuits in Superior Court in Cumberland County name New England Compounding Center in Massachusetts, as well as the doctors and health care facilities that provided the injections to treat chronic pain. They include South Jersey Regional Medical Center in Vineland and Premier Orthopaedic Associates of Southern New Jersey, which has offices in Vineland and Elmer.
Several of the patients who filed suit were hospitalized for treatment of fungal meningitis, including Jose A. Ramos, a 35-year-old Millville resident who received an injection for back pain in August. He “has suffered with headaches, visual disturbances and neck stiffness,” the lawsuit said, noting that “he will continue to take oral anti-fungal medication and pain medication … continue to receive blood testing to monitor his liver function; [and] also follow-up with CDC physicians.”
Others described severe nausea, headaches, neck pain, increased back pain, sensitivity to light, and dizziness in their suits. After the recall, one woman underwent two failed spinal taps to confirm her diagnosis before being hospitalized to undergo a third. The original reason for her injection in June was to treat back pain.

Continue reading here


Patients say their cases ignored in meningitis outbreak


Developments last week indicate that the scope of the meningitis outbreak could be wider than previously believed.

5:07PM EST November 24. 2012 - NASHVILLE -- After being treated with drugs from New England Compounding Center, 52-year-old Bret Moody was told he has fungal meningitis. He's infected with Aspergillus, the first contaminant found in a national outbreak of illness tied to tainted medication.
But when health officials count the nearly 500 people sickened by the moldy drugs, they don't include Moody and others like him who fail to match the profile of most victims.
Moody, who also has been diagnosed with leukemia, is one of many patients nationwide who question whether health officials are undercounting the victims of the crisis.
Some got the spinal steroid, methylprednisolone acetate, blamed for the meningitis outbreak that has killed at least 34 nationwide. Some, like Moody, got other drugs from the Massachusetts firm. But if their symptoms are not already linked to the outbreak, they say, medical professionals aren't taking their illnesses seriously.
Health officials say they are watching closely and haven't yet confirmed any illnesses related to other drugs from New England Compounding or its sister company, Ameridose, both of which recalled all products amid sterility concerns.
Developments last week, however, indicate that the scope of the outbreak could be wider than previously believed. The U.S. Food and Drug Administration reported finding a new batch of bacterial and fungal contaminants in drugs from New England Compounding. Meanwhile, the U.S. Centers for Disease Control and Prevention reported a surge in epidural abscesses and bone infections among patients treated with three suspect lots of methylprednisolone acetate. Previously, the dominant infection had been fungal meningitis.
Dr. Diana Zuckerman, president of the patient advocacy organization National Research Center for Women & Families, said she believes more illnesses caused by contaminated drugs may be under the radar.
"This is the tip of the iceberg," Zuckerman said.
Questions about infection
Molds such as Aspergillus are common in the environment and have been known to sicken patients with weakened immune systems in rare instances. But Moody and his wife, Joy, are convinced that his fungal infections were triggered by the drugs he was given through a port.
Like hundreds of others across the country, Bret Moody got a letter telling him that during a recent hospital stay, he was treated with drugs from New England Compounding.
Source found here

Friday, November 23, 2012

USP Sets Date for Overhaul of Monograph Naming Policy

USP Sets Date for Overhaul of Monograph Naming Policy

Exemed Pharmaceuticals to buy UCB Indian production facility

Published 23 November 2012
India-based Exemed Pharmaceuticals, a manufacturer of active ingredients, is planning to buy UCB's production facility in Vapi, Gujarat, India.
The deal, which is in line with UCB's strategy on bringing new drugs to patients and less on mass manufacturing, includes a multi-year supply agreement between both the companies.
The Vapi plant, upon completion of acquisition, will focus on the production, packaging and distribution of some of UCB's mature drugs for the Indian market.
In addition to the acquisition which brings long-term growth prospects, Exemed is planning to bring new business to the site.
The financial details of the deal have not been disclosed.

Source found here

The 2012 fungal meningitis outbreak: Slow and deadly


Close gaps in drug regulation

2:47 AM, Nov 23, 2012


In a time of sharp resentment toward government regulation in this country, the meningitis outbreak that has hit Tennessee and other states with devastating force provides a clear example that there are cases in which strong and comprehensive oversight of industry is absolutely vital.
A report by The Tennessean published Nov. 18 detailed how Colorado state inspectors knew of problems with New England Compounding Center’s interstate business practices in 2011. While they notified the U.S. Food and Drug Administration, neither the FDA nor (until a year later) the Colorado officials spoke to the Massachusetts Board of Registration in Pharmacy, which licensed NECC and presumably would have taken action against the drug compounder quickly.
Why the lapse in what would seem to be a logical chain of communication? According to a spokeswoman for the Colorado regulatory board, “We historically have not reported actions to other state boards, because in most states the registrants are required to report the actions (themselves).”
Amazing. And yet, all too common. In America, we expect oil companies to self-report about carelessness that could lead to spills, and banks to self-report when improper lending practices have been detected.
Expect the logical extension of this brand of thinking soon: In future, armed robbers must turn themselves in to authorities, or else face a stern reprimand. Police forces could be cut by half.
So far, 13 people have died and 82 been sickened in Tennessee, and 34 dead and 490 sickened nationwide, because NECC was able to continue manufacturing and shipping contaminated drugs though individual state and federal authorities were aware of problems with the company. Those numbers are expected to grow, as health officials continue to find potentially dangerous injection-site infections.
But at least there is no onerous government regulation of the drug-compounding industry.
It is hard to imagine that anyone who works in health care ever thought self-reporting was a good idea. The decision-makers at NECC had two goals: make money, and don’t get caught. Self-reporting? That would be counterproductive.
Those who argue so loudly for across-the-board deregulation should have to sit down for a talk with someone whose husband, wife or child received a steroidal injection for back pain, only to develop deadly fungal meningitis.
Afterward, perhaps they would join this newspaper in calling for Congress to establish a national data center for information on disciplinary actions involving licensed pharmacies, with requirements that state pharmacy inspectors communicate not only with the FDA, but with pharmacy boards in states where the cited company has operations.
It is not regulators who committed these crimes of malice or negligence; it was the drug makers. But we cannot waste any more lives while we wait for them to police themselves.
Source found here

Suit filed in meningitis outbreak

Suit filed in meningitis outbreak

CDC to release new report on meningitis outbreak


The CDC is set to release a new report on the fungal meningitis outbreak.
The death toll continues to climb with the latest deaths coming out of Michigan and Indiana.
The Michigan Department of Community Health said two more people have died bringing the death toll to 10 and a sixth person has died in Indiana.
Source found here

Current Version of Statute and Regulations in Arkansas Board of Pharmacy

to view the November 2012 version click here

Dispensing Drugs, Manufacturing Drugs, and Compounding Drugs


Question

What is a compounding pharmacy and how is it regulated?
Response from James L. Lindon, PharmD, PhD, JD

Director, Pharmacy Law and Intellectual Property, Lindon & Lindon, LLC
It is easy to differentiate between your local community pharmacy and a large pharmaceutical manufacturer. The pharmacy is viewed as dispensing medications to particular patients with prescriptions from a licensed provider. In contrast, the pharmaceutical manufacturer makes large batches of drug products to be distributed to pharmacy hospitals and other resellers and users of these products.
But there is another entity that falls between these: the compounding pharmacy. To be more precise, the distinctions may best be understood as different types of activities -- dispensing drugs, manufacturing drugs, and compounding drugs -- rather than merely different types of businesses. A pharmacy, which is considered a terminal distributor of dangerous drugs, may be actively dispensing, manufacturing, and compounding.
To understand why we have compounding by pharmacies, we should first understand some of the problems that patients encounter when getting prescription medications. Consider that a patient may need, for example, 15 mg of a particular medication to treat a condition. The pharmaceutical manufacturer of the medication may make only 10-mg and 20-mg tablets. To obtain a 15-mg dose, the patient may buy 10-mg tablets, cut them in half, and take 3 of the halved (5 mg) tablets. Although the math works out just fine, many patients resist this approach; they may not want to cut tablets in half or may not be able to cut tablets in half. Furthermore, splitting tablets can lead to imprecise dosing.
So, why doesn’t the pharmaceutical manufacturer make a 15-mg tablet? One reason may be money. Although a few patients may require a 15-mg dose, most patients may be treated just fine with a 10-mg or 20-mg dose; there may simply not be enough demand to justify mass production of a 15-mg tablet. At some point, the manufacturer has to draw the proverbial line and produce those products and doses that make economic sense to them.
Seeing this as an opportunity, a compounding pharmacy may begin to prepare the 15-mg tablets -- and do so in a profitable manner which the manufacturer could not or would not do. To use another example, a compounding pharmacy may prepare medications without a particular ingredient to which some patients are allergic, such as coloring agents and dyes. Without the compounding pharmacy, some patients may find themselves "stranded" and unable to obtain the medications they need.

Who Regulates Compounding by Pharmacies?

State boards of pharmacy typically regulate compounding by pharmacies, but federal legislation also plays a role. In the state of Ohio, for example, compounding is defined as preparation, mixing, assembling, packaging, and labeling of 1 or more drugs pursuant to a prescription issued by a licensed health professional authorized to prescribe drugs. [1,2]
Ohio state law also allows compounding in anticipation of orders for drugs pursuant to prescriptions based on routine regularly observed dispensing patterns. This means that a pharmacist may compound medications even though the pharmacist does not yet have a written prescription in hand for those medications, provided that the pharmacist reasonably anticipates receiving prescriptions in the future. This allows the pharmacist to make batches of medications. This is important because compounding can require significant amounts of time to complete and it may be difficult to make very small quantities of particular medications. Under Ohio law, a pharmacy may not sell a compounded drug to another pharmacy or a wholesaler. In Ohio, compounded drug preparations must be assigned beyond-use dates that are based on stability and sterility. [1,2]
State boards of pharmacy can and do enforce regulations pertaining to pharmaceutical compounding. For example, in 2006, the Ohio State Board of Pharmacy took action against Home Medical Enhancement Services, Inc. [3] The Board alleged that the company prepared subpotent medications and did not properly sterilize some compounded medications. The Board alleged that there was fungal contamination in some of the company's pulmonary products. State boards of pharmacy also can and do promulgate and enforce sterile compounding standards. [4]

Renewed Regulatory Interest

The matter of regulating compounding pharmacies (or compounding by pharmacies) and manufacturers recently gained renewed attention when an operation in Massachusetts allegedly prepared and distributed corticosteroids that were administered to patients who subsequently developed serious fungal infections. Some of these patients died. According to reports from the Centers for Disease Control and Prevention, the New England Compounding Center and its sister company Ameridose were involved in the production and eventual recall of methylprednisolone acetate (MPA) and other products in September 2012. [5] The methylprednisolone was particularly prone to sterility concerns because it was produced without antimicrobial preservatives, a common practice for medications injected into the fluid of the central nervous system.
Continue reading here

The Network - Compounding Pharmacies: Moving Forward to Protect Public Health

The Network - Compounding Pharmacies: Moving Forward to Protect Public Health

Judge orders pharmacy’s assets frozen

Judge orders pharmacy’s assets frozen

R.I. pharmacy told to stop making medicines | The Portland Press Herald / Maine Sunday Telegram

R.I. pharmacy told to stop making medicines | The Portland Press Herald / Maine Sunday Telegram

FDA needs teeth to regulate drug compounders

Nov 23, 2012


The following editorial appeared in the St. Louis Post-Dispatch on Monday, November 19:
___
Congress is looking for someone to blame for the fungal meningitis outbreak linked to steroid injections that so far has killed 34 people and sickened nearly 500. In hearings last week, partisan politics took the place of fact-finding.
Republicans on the House Energy and Commerce Committee accused Margaret Hamburg, commissioner of the Food and Drug Administration, of not acting fast enough to shut down the Massachusetts pharmacy that is linked to the outbreak.
Democrats on the subcommittee conducting the hearings defended Dr. Hamburg. They said it was the responsibility of Congress to clear up "any ambiguity" that may exist in policing compounding pharmacies.
For her part, Dr. Hamburg asserted that oversight of the nation's specialty drugmakers falls through cracks in the regulatory system. No single agency has clear authority, she said, calling on Congress to give the FDA more and better-defined regulatory power.
"We need strong, clear appropriate legislation," Dr. Hamburg said. "We cannot have a crazy quilt where different parts of the country" have different rules.
People have died. Others still are sick and suffering the consequences of the tainted drug.
Congress should stop pointing fingers and write the sort of laws that will make it clear the FDA has authority over every step of the making of compounded drugs. Such drugs are for small-batch specialty medications not readily available.
Dr. Hamburg testified that the law doesn't even include a clear definition of what compounding is, and that conflicting court decisions on the matter have further mucked up the findings on regulatory responsibility.
There are two distinctly different types of drug compounding. One is the type that was done by the New England Compounding Center of Framingham, Mass., which is where the tainted injectable steroid used to treat back and joint pain was made. The company has shut down, surrendered its license and recalled all its products since the problem was discovered.
For 20 years such large compounding companies have been at the center of dire warnings about the potential for health hazards, and have been threatened with federal intervention. The compounders dodged tough federal oversight by positioning themselves as lower-cost, community-based alternatives to "big pharma."
Even though the current attack on the FDA is partisan, the effort to help compounders dodge oversight was bipartisan. Both the late Sen. Edward M. Kennedy, D-Mass., and former House Majority Leader Tom DeLay, R-Texas, aided the industry.
The big compounders function more like big pharmaceutical firms, but without the regulatory oversight that is so successful at ensuring the drugs you buy are untainted.
The second type of compounding pharmacies are more like neighborhood drug stores that mix medicines for individual parties. These clearly fall under state jurisdiction, while the FDA has clear authority to regulate drug companies.
It's the middle ground, which includes the big compounders, where the law is cloudy.
The problem has grown in the last two decades, just as compounding has grown. Their potions were used to help fill gaps during periods of drug shortages. Sometimes they were offered as less-expensive versions of commercial drugs.
With the accelerated market for compounded drugs, abuses occurred as compounders in the basically unregulated industry sought to make their potions even cheaper. One industry critic said specially mixed drugs don't have as much protection as do drugs manufactured for use on cats and dogs.
The recent deaths and illnesses are a call to action. People and business don't like regulations until they need them. There is no louder bell to ring than 32 deaths and hundreds of sick people.
Congress should give FDA the authority it needs to ensure that drug compounding is done with the same degree of professionalism and scrutiny that goes into drug manufacturing.
___
(c)2012 St. Louis Post-Dispatch
Visit the St. Louis Post-Dispatch at www.stltoday.com